Revolution Medicines, Inc. $RVMD is DAFNA Capital Management LLC's 3rd Largest Position

Key Points

• DAFNA Capital Management LLC holds 6.6% of Revolution Medicines, making it the firm’s 3rd largest position after increasing its shares by 4.0% in the first quarter.
• Revolution Medicines recently posted a quarterly EPS of ($1.31), missing consensus estimates and resulting in a forecasted EPS of -3.49 for the current fiscal year.
• Thirteen research analysts have rated Revolution Medicines with a "Buy" rating, and the average target price is set at $69.92.

DAFNA Capital Management LLC boosted its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 4.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 656,176 shares of the company's stock after buying an additional 25,000 shares during the period. Revolution Medicines makes up about 6.6% of DAFNA Capital Management LLC's holdings, making the stock its 3rd biggest position. DAFNA Capital Management LLC owned approximately 0.35% of Revolution Medicines worth $23,202,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Revolution Medicines by 11.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,221 shares of the company's stock worth $232,000 after purchasing an additional 615 shares during the period. SG Americas Securities LLC raised its holdings in shares of Revolution Medicines by 516.0% during the first quarter. SG Americas Securities LLC now owns 18,103 shares of the company's stock worth $640,000 after acquiring an additional 15,164 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Revolution Medicines by 349.7% during the first quarter. PNC Financial Services Group Inc. now owns 4,524 shares of the company's stock valued at $160,000 after purchasing an additional 3,518 shares during the last quarter. Baker BROS. Advisors LP increased its position in Revolution Medicines by 4.9% in the 4th quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock worth $347,163,000 after purchasing an additional 367,882 shares during the last quarter. Finally, Lunate Capital Ltd purchased a new stake in shares of Revolution Medicines during the 1st quarter worth about $77,658,000. Institutional investors and hedge funds own 94.34% of the company's stock.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $37.97 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.79 and a current ratio of 11.79. The stock's 50-day simple moving average is $37.26 and its 200 day simple moving average is $38.21. The company has a market cap of $7.10 billion, a P/E ratio of -8.44 and a beta of 1.16. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.37). During the same quarter in the prior year, the business earned ($0.81) earnings per share. The business's revenue was up .0% on a year-over-year basis. As a group, sell-side analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on RVMD. Lifesci Capital started coverage on Revolution Medicines in a research note on Monday, August 18th. They issued an "outperform" rating and a $80.00 price target for the company. Wedbush restated an "outperform" rating and set a $73.00 price target (up previously from $67.00) on shares of Revolution Medicines in a report on Tuesday, June 24th. The Goldman Sachs Group initiated coverage on Revolution Medicines in a research report on Tuesday, July 15th. They issued a "buy" rating and a $65.00 price target for the company. Needham & Company LLC decreased their price objective on shares of Revolution Medicines from $57.00 to $56.00 and set a "buy" rating for the company in a report on Thursday, August 7th. Finally, Piper Sandler assumed coverage on shares of Revolution Medicines in a report on Monday, August 18th. They issued an "overweight" rating and a $75.00 target price on the stock. Thirteen research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $69.92.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.